GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » ROA %

Alseres Pharmaceuticals (Alseres Pharmaceuticals) ROA % : -399.38% (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Alseres Pharmaceuticals's annualized Net Income for the quarter that ended in Jun. 2014 was $-1.28 Mil. Alseres Pharmaceuticals's average Total Assets over the quarter that ended in Jun. 2014 was $0.32 Mil. Therefore, Alseres Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2014 was -399.38%.

The historical rank and industry rank for Alseres Pharmaceuticals's ROA % or its related term are showing as below:

ALSE's ROA % is not ranked *
in the Biotechnology industry.
Industry Median: -34.765
* Ranked among companies with meaningful ROA % only.

Alseres Pharmaceuticals ROA % Historical Data

The historical data trend for Alseres Pharmaceuticals's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals ROA % Chart

Alseres Pharmaceuticals Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,317.48 81.79 -912.03 -289.36 -139.45

Alseres Pharmaceuticals Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -828.69 -1,018.95 366.28 -354.61 -399.38

Competitive Comparison of Alseres Pharmaceuticals's ROA %

For the Biotechnology subindustry, Alseres Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alseres Pharmaceuticals's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alseres Pharmaceuticals's ROA % distribution charts can be found below:

* The bar in red indicates where Alseres Pharmaceuticals's ROA % falls into.



Alseres Pharmaceuticals ROA % Calculation

Alseres Pharmaceuticals's annualized ROA % for the fiscal year that ended in Dec. 2013 is calculated as:

ROA %=Net Income (A: Dec. 2013 )/( (Total Assets (A: Dec. 2012 )+Total Assets (A: Dec. 2013 ))/ count )
=-0.942/( (0.966+0.385)/ 2 )
=-0.942/0.6755
=-139.45 %

Alseres Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2014 is calculated as:

ROA %=Net Income (Q: Jun. 2014 )/( (Total Assets (Q: Mar. 2014 )+Total Assets (Q: Jun. 2014 ))/ count )
=-1.284/( (0.364+0.279)/ 2 )
=-1.284/0.3215
=-399.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2014) net income data. ROA % is displayed in the 30-year financial page.


Alseres Pharmaceuticals  (OTCPK:ALSE) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2014 )
=Net Income/Total Assets
=-1.284/0.3215
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.284 / 0.072)*(0.072 / 0.3215)
=Net Margin %*Asset Turnover
=-1783.33 %*0.224
=-399.38 %

Note: The Net Income data used here is four times the quarterly (Jun. 2014) net income data. The Revenue data used here is four times the quarterly (Jun. 2014) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Alseres Pharmaceuticals ROA % Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466
Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.
Executives
Mark Jerome Pykett officer: President and COO 223A MAIN ST, BOXFORD MA 021921
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Peter G Savas director, officer: Chief Executive Officer 110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston director C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr officer: Exec VP of Fin & Admin & CFO C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon officer: Chief Financial Officer 1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck director P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines